Cinclus Pharma Holding Ab
Clinical trials sponsored by Cinclus Pharma Holding Ab, explained in plain language.
A pharmaceutical holding company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New GERD drug shows promise in major trial
Disease control OngoingThis study tests a new medication, linaprazan glurate, to see if it heals esophagus damage from acid reflux better than a standard drug. About 500 adults with erosive esophagitis will take either the new drug or lansoprazole daily for up to 8 weeks. Doctors will use cameras to ch…
Phase: PHASE3 • Sponsor: Cinclus Pharma Holding AB • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New GERD drug aims to keep esophagus healed, but trial never started
Disease control TerminatedThis study was designed to see if a new drug called linaprazan glurate could keep the esophagus healed in people with GERD-related erosive esophagitis, compared to an existing drug (lansoprazole). Participants would have taken daily pills for up to 52 weeks and had regular camera…
Phase: PHASE3 • Sponsor: Cinclus Pharma Holding AB • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC